



Alnylam Large Put Sale as Vote of Confidence Upside Continues

Ticker/Price: ALNY (\$132.50)

Analysis:

Alnylam (ALNY) nice bull flag and 1000 May \$140 ITM puts being sold to open for \$16, an aggressive bull signal in a name has 2800 May \$120 calls in open interest from buyers and seen September \$145/\$175 call spreads open the past two weeks. ALNY shares forming a nice bull flag as it looks to work even higher after consolidating much of the last few months, the current flag measures to a target of \$155. ALNY is involved with RNAi Therapeutics as a new class of innovative medicines with transformational potential. Onpattro is the first approved RNAi Therapeutic targeting ATTR Amyloidosis. The \$14.55B Biotech expects 115% growth in revenues this year and 83% next year, and is partnered with Medicine Co. (MDCO) on Iclisiran, which was bought out recently. Analysts have an average target of \$140 and short interest low at 4.5% of the float for a Biotech growth name. Chardan raised its atrget to \$190 in December after positive ILLUMINATE-A Phase 3 data with NDA and MAA submission expected early 2020. ALNY noted in early February its current cash will support operations for multiple years. ALNY is now a commercial growth story with a robust pipeline. Hedge Fund ownership fell 12% in Q4 filings, Maverick reducing while Slate Path, Artal Group and Bridger all added.

Hawk Vision:



Hawk's Perspective: ALNY looks very strong here and fits that desired Biotech criteria of early commercial growth, definitely a name that could attract M&A interest.

Confidence Ranking: \$\$